Osimertinib combined with chemotherapy as fi rst-line treatment in EGFR-mutant advanced NSCLC patients: The fi rst real-world analysis in China

被引：0
|
作者：
Ji, W. [1 ]
Yu, Y. [1 ]
Ai, X. [1 ]
Chen, Z. [1 ]
Zhou, Z. [1 ]
Li, Z. [1 ]
机构：
[1] Shanghai Liao Tong Univ, Shanghai Chest Hosp, Med Oncol, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.10.732
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
699P
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Genomic profiles in EGFR mutant locally advanced or metastatic NSCLC patients after fi rst-line osimertinib treatment failure: A real-world, multi-center prospective study in China
    Shi, Y-k.
    Lv, D.
    Feng, W.
    Liu, S.
    Xing, P.
    Yu, Y.
    Yin, J.
    Ren, X.
    Zhang, J.
    Han, G.
    Zhang, Y.
    Cang, S.
    Chen, J.
    Chen, E.
    Meng, L.
    Zhang, Y.
    ANNALS OF ONCOLOGY, 2024, 35
  • [2] Real-world effectiveness and safety of fi rst-line (1L) osimertinib for EGFR-mutated (EGFRm) advanced NSCLC: A prospective, multi-center, real-world study in China (FLOURISH Study)
    Zhou, J.
    Shen, L.
    Lv, D.
    Tang, K.
    Zhu, D.
    Zhao, Y.
    Wang, K.
    Wang, Y.
    Xing, L.
    Cui, J.
    Ding, L.
    Shi, X.
    Zheng, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S1653 - S1654
  • [3] Osimertinib combined with bevacizumab and chemotherapy as fi rst-line treatment in EGFR-mutated advanced nonsquamous non-small cell lung cancer with concurrent mutations
    Xiong, Y.
    Wang, Y.
    Zhang, W.
    Shen, M.
    Li, S.
    Zhang, X.
    Ren, X.
    Wang, S.
    Liu, L.
    ANNALS OF ONCOLOGY, 2024, 35
  • [4] Ibrutinib as fi rst-line therapy for mantle cell lymphoma: a multicenter, real-world UK study
    Tivey, Ann
    Shotton, Rohan
    Eyre, Toby A.
    Lewis, David
    Stanton, Louise
    Allchin, Rebecca
    Walter, Harriet
    Miall, Fiona
    Zhao, Rui
    Santarsieri, Anna
    Mcculloch, Rory
    Bishton, Mark
    Beech, Amy
    Willimott, Victoria
    Fowler, Nicole
    Bedford, Claudia
    Goddard, Jack
    Protheroe, Sam
    Everden, Angharad
    Tucker, David
    Wright, Josh
    Dukka, Vasavi
    Reeve, Miriam
    Paneesha, Shankara
    Prahladan, Mahesh
    Hodson, Andrew
    Qureshi, Iman
    Koppana, Manasvi
    Owen, Mary
    Ediriwickrema, Kushani
    Marr, Helen
    Wilson, Jamie
    Lambert, Jonathan
    Wrench, David
    Burney, Claire
    Knott, Chloe
    Talbot, Georgina
    Gibb, Adam
    Lord, Angela
    Jackson, Barry
    Stern, Simon
    Sutton, Taylor
    Webb, Amy
    Wilson, Marketa
    Thomas, Nicky
    Norman, Jane
    Davies, Elizabeth
    Lowry, Lisa
    Maddox, Jamie
    Phillips, Neil
    BLOOD ADVANCES, 2024, 8 (05) : 1209 - 1219
  • [5] Mechanisms of acquired resistance to fi rst-line (1L) osimertinib in EGFR-mutated (EGFRm) advanced NSCLC: Results from a prospective, multi-center, real-world study in China (FLOURISH study)
    Zhou, J.
    Shen, L.
    Lv, D.
    Tang, K.
    Zhu, D.
    Zhao, Y.
    Wang, K.
    Wang, Y.
    Xing, L.
    Cui, J.
    Ding, L.
    Shi, X.
    Zheng, J.
    Zhou, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S1663 - S1663
  • [6] First line osimertinib for the treatment of patients with advanced EGFR-mutant NSCLC
    Ricciuti, Biagio
    Chiari, Rita
    TRANSLATIONAL LUNG CANCER RESEARCH, 2018, 7 : S127 - S130
  • [7] Real-world outcomes of fi rst-line platinum doublet chemotherapy plus Tyrosine Kinase Inhibitors (TKI) in advanced epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC)
    Low, Y. F.
    Lai, G.
    Seet, A.
    Tan, W. C.
    Tan, A. C.
    Chan, J.
    Teh, Y. L.
    Tan, W. L.
    Jain, A.
    Ng, Q. S.
    Ang, M-K
    Kanesvaran, R.
    Lim, D. W. T.
    Tan, D. S. W.
    Saw, P. L. S.
    ANNALS OF ONCOLOGY, 2024, 35 : S1656 - S1657
  • [8] Osimertinib with chemotherapy as fi rst-line therapy for patients with locally advanced or metastatic epidermal growth factor receptor mutation (EGFRm) non-small cell lung cancer (NSCLC): A prospective, multi-centre, real-world study (FOREFRONT)
    Han, B.
    Wang, Q.
    Zhang, B.
    Lv, D.
    Yao, W.
    Yu, Y.
    Zhuo, M.
    ANNALS OF ONCOLOGY, 2024, 35
  • [9] First-line osimertinib compared to earlier generation TKIs in advanced EGFR-mutant NSCLC: A real-world survival analysis
    Gomez-Randulfe, Igor
    Scanlon, Lauren A.
    Carter, Mathew
    Moliner, Laura
    Cil, Emine
    Califano, Raffaele
    Summers, Yvonne
    Blackhall, Fiona
    Lindsay, Colin R.
    Lewis, Jacob
    Gomes, Fabio
    LUNG CANCER, 2025, 200
  • [10] Comparison of performance of MET amplification detection by FISH, NGS and ddPCR in EGFRm advanced NSCLC patients post fi rst-line osimertinib treatment failure: Analysis from a prospective, multi-center study in China
    Xing, P.
    Lv, D.
    Feng, W.
    Liu, S.
    Yu, Y.
    Yin, J.
    Ren, X.
    Zhang, J.
    Han, G.
    Zhang, Y.
    Cang, S.
    Chen, J.
    Chen, E.
    Meng, L.
    Zhang, Y.
    Shi, Y-k.
    ANNALS OF ONCOLOGY, 2024, 35
12345